US-based Sunflower Therapeutics has announced its first distribution agreement with PharmNXT Biotech, an Indian bioprocessing company. Through this agreement, Sunflower will commercially launch its Daisy Petal Perfusion Bioreactor System in Asia, a significant step in the company’s ongoing product commercialization.
Sunflower’s innovative Daisy Petal perfusion fermentation system uses a single-use assembly designed specifically for intuitive installation and a simple user experience. The system’s hardware and controls are engineered and optimised for in-vessel perfusion utilising a custom disposable stirred tank reactor outfitted with a unique in-vessel perfusion device that enables greater volumetric productivity from the bench through scale-up manufacturing. With this approach, the system boasts space-time yield benefits five-to-ten times greater compared to traditional fed-batch methods for the production of diverse proteins.
Ankush Kapoor, Co-founder and CEO of PharmNXT Biotech, and Sachin Joshi, Co-founder and Managing Director of PharmNXT Biotech said, “Sunflower, with its innovative technologies, and PharmNXT, with our technical expertise and experience in Asia, are taking an important step forward in our collaboration by leveraging our strengths in efficiency and quality to make biopharmaceuticals affordable and accessible.
In addition to the hardware, Sunflower’s bioprocessing software suite, which is compliant with Good Manufacturing Practices (GMP), includes HelianthOS, Nursery, and Harvest. These tools enable walkaway automation of fermentation processes, easy to develop recipes that require no coding and secure storage of process data. Together, these three elements provide a cohesive ecosystem that enables efficient and intuitive operations throughout an entire campaign.
